Abstract:Objective To investigate the risk factors of proteinuria in tumor patients treated with bevacizumab.Methods A retrospective analysis was performed on the clinical data of 205 patients with advanced tumor receiving bevacizumab treatment at the First Affiliated Hospital of Suchow University from June 2017 to June 2020 (including 130 colorectal cancer patients,69 non-small cell lung cancer patients,2 cervical cancer patients,2 ovarian cancer patients and 2 breast cancer patients).According to the urinary protein level after medication,the patients were divided into proteinuria group (n=30) and non-proteinuria group (n=175).Logistic regression model was used to analyze the risk factors of proteinuria in two groups,and receiver operating characteristic (ROC) curve was drawn to determine the best critical value for proteinuria.Results The logistic regression model showed that large cumulative dose of bevacizumab(OR=1.224,95%CI:1.082-1.383,P=0.001)and high systolic blood pressure(OR=1.039,95%CI:1.009-1.069,P=0.011)were the independent factors for proteinuria.ROC curve analysis found that the best critical value of cumulative dose of bevacizumab for diagnosing proteinuria was 3.1 g,and the systolic blood pressure was 154 mm Hg.In proteinuria group,12 patients stopped taking the drug,and 8 patients presented with negative or low proteinuria.Conclusions Large cumulative dose and high systolic blood pressure are the risk factors for proteinuria in the patients receiving bevacizumab chemotherapy.Early with drawal of bevacizumab can reduce the incidence of proteinuria.